XML 19 R33.htm IDEA: XBRL DOCUMENT v3.2.0.727
Licensing, Acquisitions and Other Arrangements (Details 2) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
May. 26, 2015
Dec. 31, 2014
Assets acquired and liabilities assumed              
Goodwill $ 13,209 $ 13,209   $ 13,209     $ 5,862
Net Revenues   5,475 $ 4,926 10,515 $ 9,489    
Operating loss   1,852 1,515 3,539 2,866    
Amortization of Intangible Assets   86 $ 99 154 $ 209    
Pharmacyclics Inc              
Assets acquired and liabilities assumed              
Cash and equivalents           $ 877  
Short-term investments           11  
Accounts and other receivables           106  
Inventories           509  
Other assets           212  
Accounts payable and accrued liabilities           (381)  
Deferred income taxes           (6,452)  
Other long-term liabilities           (254)  
Total identifiable net assets           13,168  
Goodwill           7,602  
Total assets acquired and liabilities assumed           20,770  
Fair market value step-up adjustment to inventories 462 $ 462   $ 462      
Amortized period of inventory       18 months      
Finite intangible assets weighted-average estimated useful life       13 years      
Net Revenues 107            
Operating loss 337            
Acquisition-related compensation expense 226            
Acquisition-related inventory step up and amortization of intangible assets 39            
Acquisition-related transaction and integration costs       $ 89      
Pharmacyclics Inc | IPR&D              
Assets acquired and liabilities assumed              
Intangible assets           7,170  
Pharmacyclics Inc | Developed product rights              
Assets acquired and liabilities assumed              
Intangible assets           4,590  
Pharmacyclics Inc | License agreements              
Assets acquired and liabilities assumed              
Intangible assets           $ 6,780  
Pharmacyclics Inc | Selling, general and administrative expense              
Assets acquired and liabilities assumed              
Acquisition-related costs 222            
Pharmacyclics Inc | R&D              
Assets acquired and liabilities assumed              
Acquisition-related costs 93            
Pharmacyclics Inc | Cost of products sold              
Assets acquired and liabilities assumed              
Acquisition-related costs $ 39